Nivolumab in platinum-refractory unresectable locally advanced squamous cell carcinoma of the head and neck: A case report and literature review
Oral Oncology Reports · 2025-03 · 13 · 100725
DOI: 10.1016/j.oor.2025.100725 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oral Oncology Reports, 2025-03. Verfasst von M.S. Ruban und 1 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) is associated with high mortality and poses a significant public health challenge. Platinum-based chemotherapy is a primary treatment modality; however, the median survival for patients experiencing recurrence within six months of platinum-based therapy is no more than six months. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have revolutionized the treatment of platinum-refractory HNSCC since their FDA approval in 2016. This case report highlights the successful use of nivolumab in a patient with platinum-refractory, unresectable HNSCC, achieving long-term survival of over six years. The patient demonstrated a significant tumor reduction and stabilization of disease, followed by successful surgical management of recurrent lymph node growth. This case underscores the potential for durable responses with nivolumab, even in the absence of PD-L1 testing, and highlights the integration of immunotherapy with surgery as a personalized treatment strategy. The findings contribute to the growing body of real-world evidence supporting the use of immune checkpoint inhibitors in platinum-refractory HNSCC. • Long-term survival over six years with nivolumab in platinum-refractory HNSCC. • Nivolumab and surgery highlight a personalized treatment strategy. • Real-world evidence of nivolumab efficacy without PD-L1 testing. • Adds to literature on immune checkpoint inhibitors in advanced HNSCC.
Zitieren
APA
Ruban, M., & Bolotina, L. (2025). Nivolumab in platinum-refractory unresectable locally advanced squamous cell carcinoma of the head and neck: A case report and literature review. Oral Oncology Reports, 13, 100725. https://doi.org/10.1016/j.oor.2025.100725
Vancouver
Ruban M, Bolotina L. Nivolumab in platinum-refractory unresectable locally advanced squamous cell carcinoma of the head and neck: A case report and literature review. Oral Oncology Reports. 2025;13:100725. doi:10.1016/j.oor.2025.100725
BibTeX
@article{Ruban2025,
author = {Ruban, M.S. and Bolotina, L.V.},
title = {Nivolumab in platinum-refractory unresectable locally advanced squamous cell carcinoma of the head and neck: A case report and literature review},
journal = {Oral Oncology Reports},
year = {2025},
volume = {13},
pages = {100725},
doi = {10.1016/j.oor.2025.100725}
}
EUVIMED